Ethan Carter

📊 Institutional-Grade Price Action Trader
⚡Precision Entries Confirmed by Volume

EDGE:
▫️ Key S/R Flips
▫️ RSI+Volume Profile Divergence
▪️ 85% Win
▪️ 21 Yr

[Ethan Carter @0611_hinon]

Key insight: $ZTS's 8% drop signals that even resilient sectors like pet care are facing economic headwinds. While profitability holds, the lowered sales range may prompt a valuation reassessment amid slowing volume growth. #Trading #Stocks

[Ethan Carter @0611_hinon]

$NCLH plunges ~10% premarket after Q3 revenue of $2.94B missed the $3.02B estimate, signaling weaker-than-expected cruise demand. Despite raising its adjusted EPS outlook, the top-line shortfall spooks investors. #Travel #Stocks

[Ethan Carter @0611_hinon]

Broadridge $BR kicks off FY2026 with a bang! Profits soared, more than doubling year-over-year. This strong performance, fueled by its dominant investor communications business, puts the firm on track to hit the high end of its full-year growth guidance.

[Ethan Carter @0611_hinon]

Join our global WhatsApp stock community! 🌍

Get the latest market trends, news, and daily stock picks directly on your phone.

WhatsApp: https://t.co/uFXXDJ3Rxk

Simply message "5" to join for FREE! 🚀

#Stock #investing

[Ethan Carter @0611_hinon]

Today's Focus: $TVTX
Look for entry after market open.

Catalyst: FDA approval for FSGS treatment expected January 2026 . This addresses an unmet market need with potential >$300M US sales opportunity . Strong Q3 results: EPS $0.59 (beat est.)

#Stocks
Not investment advice.

[Ethan Carter @0611_hinon]

Today's Focus: $SLDP
Look for entry after market open.

Catalyst: BMW i7 test vehicle powered by SLDP cells marks key partnership milestone . SK On pilot line factory acceptance testing completed. U.S. DOE award up to $50M for electrolyte production.

Not investment advice.

[Ethan Carter @0611_hinon]

Today's Focus: $ATEC
Look for entry after market open.

Catalyst: Strong revenue growth (up ~25% in spine market) and analyst optimism (Piper Sandler) . 1-year analyst target: $19.38 .

#Stocks
Not investment advice.

[Ethan Carter @0611_hinon]

Join our global WhatsApp stock community! 🌍

Get the latest market trends, news, and daily stock picks directly on your phone.

WhatsApp: https://t.co/uFXXDJ3Rxk

Simply message "5" to join for FREE! 🚀

#Stock #investing

[Ethan Carter @0611_hinon]

Today's Focus: $COMM
Look for entry after market open.

Catalyst: Added to Deutsche Bank's "Catalyst Call Buy" list, a short-term bullish signal . Q3 earnings release today (Oct 30) is a key near-term focal point .

#Stocks
Not investment advice.

[Ethan Carter @0611_hinon]

Today's Focus: $IBIO
Look for entry after market open.

Catalyst: Key obesity drug candidate IBIO-610 shows promise in preclinical data for fat loss & muscle preservation . Near-term data presentation at ObesityWeek in November 2025 is a key milestone .

Not investment advice.

[Ethan Carter @0611_hinon]

Today's Focus: $TECX
Look for entry after market open.
Catalyst: Positive Phase 1b topline results for TX45 in heart failure (PH-HFrEF) just released . Stock reacted +26.64% pre-market .

#TECX #Biotech #Stocks
Not investment advice.

[Ethan Carter @0611_hinon]

Today's Focus: $JAMF
Look for entry after market open.

Catalyst: Landed a 5-year contract with Inter-University Council of Ohio for its RapidIdentity platform, serving 86 institutions . Positive analyst sentiment with average price target $14.40.

#Stocks
Not investment advice.

[Ethan Carter @0611_hinon]

Today's Focus: $HAYW
Look for entry after market open.
Catalyst: Strong Q3 results: revenue $187.2M (beat est.), EPS $0.68 (beat $0.60 est.) . Raised FY2025 guidance .

#HAYW #Stocks
Not investment advice.

[Ethan Carter @0611_hinon]

Today's Focus: $OPFI
Look for entry after market open.
Catalyst: Strong Q3 earnings beat : EPS $0.46 vs. $0.30 est., revenue $155.1M vs. $153.4M est. . Stock surged pre-market .

#OPFI #Stocks
Not investment advice.

[Ethan Carter @0611_hinon]

Today's Focus: $SOFI
Look for entry after market open.
Catalyst: Strong Q3 2025 results beat estimates, company raised 2025 profit forecast . Record fee-based revenue growth and expansion in crypto trading & loan platform business are key drivers .

#Stocks
Not advice.

[Ethan Carter @0611_hinon]

Today's Focus: $LUNG
Look for entry after market open.
Catalyst: Positive Phase 2 PFS data for INBR-16 in mesothelioma due Q4 2025 . Recent FDA Breakthrough Therapy designation could accelerate development timeline . High-risk biotech.

#LUNG #Stocks
Not investment advice.

[Ethan Carter @0611_hinon]

Today's Focus: $POLA
Look for entry after market open.

Catalyst: Q2 2025 earnings showed improvement: net loss narrowed to -$271K (a 78.6% improvement from the previous quarter's -$1.26M loss) .

#Stocks
Not investment advice.

[Ethan Carter @0611_hinon]

Today's Focus: $BBIO
Look for entry after market open.

Catalyst: Key Phase 3 data for BBP-812 in neurodegenerative disease due Q1 2026 . Recent FDA Fast Track designation could accelerate regulatory path . High-risk biotech.

#BBIO #Stocks
Not investment advice.

[Ethan Carter @0611_hinon]

Today's Focus: $BLNE
Look for entry after open.
Catalyst: New home equity product, stablecoin-funded. Targets profitability by Q4 2025. Spirits assets sale completes pivot to digital mortgage lending.

#Stocks
Not investment advice

[Ethan Carter @0611_hinon]

Today's Focus: $NMRA
Look for entry after market open.

Catalyst: Multiple clinical data readouts due: Phase 3 MDD data (navacaprant) in H1 2026 & Phase 1b Alzheimer's agitation data (NMRA-511) around year-end 2025.
#Stocks
Not investment advice.